SAN DIEGO, April 2, 2018 /PRNewswire-iReach/
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics to inhibit key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the publication in the Journal of Biological Chemistry studies demonstrating its dual PI3K/BRD4 inhibitor SF2523 suppresses HIV-1 replication and eliminates the latent infectious state.
The study was conducted by Dr. Donald L. Durden, founder and senior scientific advisor of SignalRx Pharmaceuticals and Professor and Associate Director of Pediatric Oncology at the Moores UCSD Cancer Center, in collaboration with researchers at the Division of Infectious Diseases at the University of California San Diego School of Medicine.
"This is a huge breakthrough because until now there has not been a mechanism to address the quiescent dormant pocket of latent HIV-1 virus infection in the AIDS population and SF2523 now is demonstrated the capacity to "shock and kill" the virus in macrophages, the dominant sanctuary site for HIV responsible for lack of efficacy of antiretroviral therapy to cure the disease" said Dr. Durden.
"This study suggests SF2523, in combination with antiretroviral therapy, could eliminate the HIV dormancy state and increase the likelihood of a cure for AIDS; this combination is worthy of clinical trials in this disease. This opens a new opportunity to expand the utility of SF2523 and other dual PI3K/BRD4 inhibitors in our pipeline to eradicate HIV virus in AIDS patients" said Dr. Joseph Garlich, SignalRx's Chief Scientific Officer.
SignalRx has a diverse portfolio of first-in-class potent and unique multi-targeted anticancer inhibitors such as PI3K/BDR4, CDK6/PI3K/BRD4, HDAC6/PI3K/BRD4, and BTK/PI3K/BRD4.
SignalRx also announces that it is interested in partnering discussions to quickly take these novel small molecules through clinical trials together with companion diagnostics for streamlined development and approval.
About SignalRx Pharmaceuticals Inc.
SignalRx is a privately held corporation based in San Diego, CA developing small molecule inhibitors of multiple key signaling pathways in cancer and cancer stem cells. The company has developed its proprietary CRIMP technology platform to develop new small-molecule therapeutics against more than one target molecule selected from the discovery of synthetic lethalities in cancer cells, epigenetic regulatory processes, immune checkpoints and DNA repair actions. SignalRx's research programs have novel inhibitors targeting multiple critical onco-targets such as PI3K, MEK, BRAF, IDO1, IDH1, CDK4/6, Wnt, HDAC, DNMT, PARP and BET bromodomains. SignalRx is leveraging its expertise in novel multi-action inhibitors to develop enhanced anticancer therapeutics with improved efficacy, novel mechanism of action in a single molecule, and the potential to streamline their development (single agent, combination therapies).
Media Contact: Guillermo Morales, SignalRx Pharmaceuticals Inc., 520-777-9609, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE SignalRx Pharmaceuticals Inc.